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diabetic-speciﬁc model. An array of scenarios were created
simulating patient adequately controlled LDL-C, both LDL-C
and HDL-C, all three lipid parameters and all modiﬁable RFs
(the previous plus smoking, SBP and HbA1c). RESULTS: A
total of 318 patients were included in this analysis. Average age
63.1 (SD 10.6) years and 47% were female. Less than 20% of
the patients presented LDL-C at target levels and ~60% of
patients show HDL-C and/or triglycerides at the recommended
levels. Among these patients SBP and HbA1c were ~20% at
target levels. Actual 5-years risk estimate was 51.6% (SD 0.3).
The proportion of maximum potential CV Risk Reduction
(calculated as Absolute Risk Reduction [ARR] divided by
maximum ARR [ARR/MaxARR]), by simulated scenarios
were: 42.4% (if LDL-C at target), 58% (if LDL-C and HDL-C
at target); 67.5% (if all three lipid-parameters at target); and if
all modiﬁable RF were at target for all patients the estimated
risk was 31.1% and the maximum risk reduction 100%. CON-
CLUSIONS: T2DM patients starting OCT frequently have their
lipids not at target increasing their CV risk. Hence to reduce
this risk it is required to comprehensively manage them in
order to achieve the maximum beneﬁt.
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OBJECTIVES: To assess the association of patient self-reported
hypoglycemic-symptoms with dose reduction of sulphonylurea
or change to another glucose-lowering drug class in adult
patients with T2DM on oral anti-hyperglycemic therapy in
Spain. METHODS: A retrospective study included patients
30 years at time of T2DM diagnosis that had added SU or
PPARg-agonist to previous MF. The information was extracted
from the patients’ clinical charts, for up to 7 months baseline
period (before SU or PPAR addition) and for a minimum of
one year follow-up period (between therapy addition and date
of survey), including: patients’ demographic characteristics,
glucose lowering therapy and HbA1c. Patient-reported
hypoglycemic episodes during the year prior to study enroll-
ment were collected, and patients were grouped according to
the most severe episode they had reported. Patients that had
not received a SU anytime in that period, and those that
received insulin anytime during this period were excluded from
the analysis. RESULTS: A total of 493 patients were recruited,
and 323 included in this analysis. Average age was 64 years
and 46.5% were female. Average time for the initiation of oral
combination therapy was 2.9 years. Their average HbA1c at
baseline was 8% and 7.1% at the end of follow-up period.
During the year prior to study enrollment, 119 patients (37%)
reported hypoglycemic episodes; 75% only mild symptoms (no
interruption of daily activities) and 25% at least one moderate
(some interruption of activities) or severe/very severe symptoms
(requiring non-medical/ medical assistance). A total of 12.4%
of the patients had their SU dose reduced, suspended or
replaced for either a glinide or a PPAR: 9% of patients without
hypoglycemic symptoms, 15.6% of patient with mild symptoms
and 24.1% of patients with from moderate to very severe
hypoglycaemic symptoms (Chi-squared, p = 0.04). CONCLU-
SIONS: Patient-reported experience of hypoglycemic symptoms
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OBJECTIVES: The aim of the analysis was to estimate the
budget impact of including long-acting insulin analogs (LAA) in
the reimbursement list. METHODS: The reimbursement list in
Poland currently includes several human insulin products, but
LAA are not reimbursed, therefore only few patients receive
them. This analysis was performed from the public payer per-
spective (National Health Fund). A 5-year time horizon was
adopted. Prognosis was based on the assumption that basal
insulin sales will increase in the same way as in the past 12 years
in Poland. Percent of market share in basal insulin market were
estimated based on other European countries. Four different
reimbursement scenarios were considered: Scenario 1 (100%
reimbursement of LAA for all insulin-treated patients) and sce-
nario 2 (50% reimbursement for all insulin-treated patients),
scenario 3 (100% reimbursement for special patient population)
and scenario 4 (50% reimbursement for special patient popula-
tion). Special patient population was deﬁned as patients who did
not obtain the desired metabolic effect with their currently used
insulin regimen and/or experienced recurrent hypoglycaemia,
particularly nocturnal. RESULTS: In case of 100 % reimburse-
ment of LAA (scenario 1), the expenditures for basal insulin will
increase by 19,598 mln PLN in 2007 and by 52,403 mln PLN in
2011. In scenario 2, the expenditure will increase by 3663 mln
PLN and 8,01 mln PLN in 2007 and 2011 respectively. In sce-
nario 3, the expenditure will increase by 11,072 mln PLN and
41,812 mln PLN in 2007 and 2011 respectively. In scenario 4 the
expenditure will increase by 2970 mln PLN and 6589 mln PLN
in 2007 and 2011 respectively. CONCLUSIONS: This analysis
shows that 100 % reimbursement of LAA for all insulin-treated
patients (scenario 1) will be associated with the highest increase
in drug expenditure In Scenarios 2–4, expenditure will rise to a
smaller extend due to restriction to special patient population
and/or co-payment.
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OBJECTIVES: To estimate the burden of diabetes mellitus (DM)
and its complications in The Netherlands. METHODS: The
PHARMO Record Linkage System comprised among others
linked drug dispensing, hospital and clinical laboratory data
from approximately 2.5 million individuals in The Netherlands.
Patients with DM were included in the study cohort during
2000–2004 if they used antidiabetic drugs or had HbA1c
6.5 mmol/l or had a hospitalisation for DM or a diabetic
complication in the measurement year or in the preceding year.
Controls free of diabetes were 1:1 matched to patients with
diabetes, on birth year, zip code and gender. Complications (hos-
pitalisations and dispensings for cardiovascular disease/eye
problems/amputations) were classiﬁed into stages. Complica-
tions attributed to DM were estimated as complication stages 1
and 2 among patients minus those among controls. Drug costs
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were extrapolated to The Netherlands by direct standardisation.
RESULTS: From 2000 to 2004, the annual prevalence of DM in
The Netherlands increased from 454,000 to 641,000 patients.
Severe cardiovascular complications attributed to diabetes
increased from 18,000 to 39,000 patients. Total cost associated
with antidiabetic drug treatment and hospitalizations, attributed
to DM, increased from €442,308,000 to €822,333,000. Most of
these costs (€535,672,000 in 2004) were due to hospitalizations.
Cost of hospitalizations and cardiovascular drugs among control
subjects increased from €275,123,000 to €608,392,000. CON-
CLUSIONS: Drug treatment, hospitalisations and cost attributed
to diabetes mellitus have almost doubled between 2000 and
2004, but so did the “background” costs in the general popula-
tion, perhaps due to preventive efforts.
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OBJECTIVES: To compare cost-utility of detemir and NPH
insulin in intensive insulin therapy (IIT) of type 1 diabetes
patients, cost-utility of detemir and NPH insulin in basal-bolus
IIT or added to oral antidiabetes treatment in type 2 diabetes.
To estimate the impact of insulin detemir reimbursement on
the budget (BIA) of the National Health Fund in Poland.
METHODS: Cost-utility analysis from payers’ (Polish National
Health Fund and patient) perspective in lifetime horizon was
conducted using CORE Diabetes Model. The effectiveness data
were derived from clinical studies. The model default values and
experts’ opinion served as data sources for resource use. BIA:
Two scenarios were compared: before and after reimbursement
of insulin detemir with reimbursement limit equal to the drug
price. Population of patients treated with insulin detemir was
assumed to consist of type 1 and type 2 patients with docu-
mented episodes of severe hypoglycaemia, undergoing IIT (with
use of standard basal insulin NPH). RESULTS: CUA: Insulin
detemir in type 1 and type 2 diabetes patients is more costly and
more effective than NPH insulin in terms of patients’ life expect-
ancy and quality adjusted life years (QALYs) gained—cost
per QALY gained is: PLN161,138 (€47,512) in type 1 diabetes
treatment; PLN603,107 (€177,829), assuming use of basal-
bolus intensive insulin therapy in type 2 diabetes; PLN72,583
(€21,401), assuming use of long-acting insulin with oral antidia-
betes drugs in type 2 diabetes. A Predicted number of patients
annually treated with insulin detemir amounts to 6 736. In case
of insulin detemir reimbursement yearly public payer’s (NHF)
expenditures for long-acting insulins used in intensive insulin
therapy would increase by PLN 6,1mln (€1,8mln), i.e. 20%
compared to a current situation. CONCLUSIONS: Type 1 and
type 2 diabetes treatment with insulin detemir offers an improve-
ment of patients’ quality of life, being more costly than standard
intensive insulin therapy with NPH.
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OBJECTIVES: To estimate the cost-utility of sitagliptin (Janu-
via®) in the treatment of type 2 diabetes and impact of Januvia®
reimbursement on Polish National Health Fund (NFZ) budget.
METHODS: Cost-utility Markov model from both payers’ per-
spective (NFZ and patient) was constructed with one year time
horizon. Target population were patients with insufﬁcient glyce-
mic control with metformin monotherapy. One comparison:
sitagliptin/metformin vs metformin/glipizide was performed in
CUA. The measure of the effects was QALY. BIA was performed
from public payers’ and both payers’ (NFZ and patient) perspec-
tive in 3-year time horizon. Two reimbursement levels were con-
sidered 30% and 100%. RESULTS: Average costs of the
treatment of diabetes were 3 218.37 PLN for SIT/MET and
1 317.76 PLN for GLI/MET. Treatment effects were 0.715 QALY
for SIT/MET and 0.687 QALY for GLI/MET. ICER value for
SIT/MET vs GLI/MET was 67 027 PLN/QALY. Assuming
100%-reimbursement, annual expenses from National Health
Fund budget would raise by 9.1 (year 2008), 15.9 (2009) and 20.5
mln PLN in year 2010. In case of 30%-reimbursement of sitaglip-
tin, incremental expenditures for NFZ would be: 6.25, 10.94 and
14.07 mln PLN in years 2008, 2009 and 2010 respectively.
Assuming both payers’ perspective annual expenses from NFZ
budget and patient would raise by: 8.3 (year 2008), 14.5 (2009)
and 18.6 mln PLN in year 2010. CONCLUSIONS: Results of the
analysis indicate that sitagliptin/metformin treatment is more
effective and more expensive than strategy with metformin/
glipizide. ICER is below the acceptable threshold (83,239 PLN),
therefore treatment with SIT can be considered as cost-effective.
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OBJECTIVES: Compare costs among patients with type 2 diabe-
tes (T2D) treated with exenatide or insulin glargine. These are
injectable agents typically used after failure on oral antidiabetic
agent(s) METHODS: Data from September 2004 to September
2007 were obtained from a large retrospective claims database.
Intent-to-treat cohorts of insulin-naïve adults diagnosedwith T2D
who initiated therapy on either exenatide (N = 4090) or insulin
glargine (N = 1660). Individuals were not allowed to use the other
medication or other insulin in the one-year follow-up period.
Annual total medical costs and total diabetes relatedmedical costs
were estimated using stepwise multivariate regressions. Major
cost components were also examined using either stepwise multi-
variate regressions or a two-part model that controlled for the
probability of using the service. Smearing estimates were used to
transform estimated log costs into costs. The analyses controlled
for the potential impact of patient demographics, general health,
prior resource use, comorbidities, and timing of treatment initia-
tion. RESULTS: Initiation with exenatide compared to insulin
glargine, was associated with signiﬁcantly lower total direct
medical costs ($19,293 vs $23,782, p < 0.001) and total diabetes-
related medical costs ($7,833 vs $8,536, p < 0.0001). Initiation of
therapy with exenatide compared to insulin glargine was also
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